Alteration of Serum IgG Galactosylation As a Potential Biomarker for Diagnosis of Neuroblastoma

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Mar 28

PMID 29581769

Citations 10

Authors

Wenjun Qin

Hao Pei

Ruihuan Qin

Ran Zhao

Jing Han

Zejian Zhang

Kuiran Dong

Shifang Ren

Jianxin Gu

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma (NB) is the most frequent pediatric malignant neoplasm that originates from embryonic neural crest cells. Urinary catecholamines in 24-h urine are most commonly analyzed for the diagnosis of neuroblastoma at good sensitivity; however, it is challenging to collect 24-h urine samples in a pediatric population. Therefore, development of more rapid, non-invasive and cost-effective tools for the diagnosis of NB remains needed. Serum immunoglobulin G (IgG) galactosylation have been found highly associated with adult cancers in our previous study. To explore the potential use of serum IgG galactosylation in aiding diagnosis of neuroblastoma, serum IgG galactosylation profiles of 26 neuroblastoma cases and 30 age-matched non-malignant controls were analyzed by MALDI MS. The alteration of IgG galactosylation in neuroblastoma patients was measured by a Gal-ratio formula: G0/(G1+G2×2), calculating the relative intensities of agalactosylated N-glycan (G0) vs mono-galactosyl N-glycan (G1) and digalactosyl N-glycan (G2). The results showed that IgG Gal-ratios were significantly higher in neuroblastoma cases compared with non-malignant controls (=5.0×10). And the Gal-ratio data generated sensitivity and specificity of 84.62% and 60.00%, combined with an AUC (area under the curve) of 0.80. The analysis of serum IgG galactosylation distribution may play a suggestive role for neuroblastoma diagnosis, or serve as a potential biomarker for NB diagnosis.

Citing Articles

Exploring serum -glycome patterns as candidate non-invasive biomarkers in inguinal hernia.

Cao Z, Zhang Z, Wang Y, Zhu Y, Li Z, Li X Heliyon. 2024; 10(16):e35908.

PMID: 39211922 PMC: 11357755. DOI: 10.1016/j.heliyon.2024.e35908.

Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.

DallOlio F, Malagolini N Exp Suppl. 2021; 112:303-340.

PMID: 34687015 DOI: 10.1007/978-3-030-76912-3_10.

Diagnostic Potential of Plasma IgG N-glycans in Discriminating Thyroid Cancer from Benign Thyroid Nodules and Healthy Controls.

Zhang Z, Wu J, Liu P, Kang L, Xu X Front Oncol. 2021; 11:658223.

PMID: 34476207 PMC: 8406750. DOI: 10.3389/fonc.2021.658223.

Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning.

Pan Y, Zhang L, Zhang R, Han J, Qin W, Gu Y Am J Cancer Res. 2021; 11(6):3002-3020.

PMID: 34249441 PMC: 8263652.

Serum Protein N-Glycosylation Signatures of Neuroblastoma.

Qin W, Pei H, Li X, Li J, Yao X, Zhang R Front Oncol. 2021; 11:603417.

PMID: 33796450 PMC: 8008057. DOI: 10.3389/fonc.2021.603417.

References

Uccini S, Mannarino O, McDowell H, Pauser U, Vitali R, Natali P . Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res. 2005; 11(1):380-9. View

Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J . Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res. 2013; 12(9):4046-55. DOI: 10.1021/pr4003992. View

Modak S, Cheung N . Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev. 2010; 36(4):307-17. DOI: 10.1016/j.ctrv.2010.02.006. View

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999; 86(2):349-63. View

Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T . Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med. 1988; 167(5):1731-6. PMC: 2188930. DOI: 10.1084/jem.167.5.1731. View

Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O . High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011; 10(10):M111.010090. PMC: 3205872. DOI: 10.1074/mcp.M111.010090. View

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

Bakovic M, Selman M, Hoffmann M, Rudan I, Campbell H, Deelder A . High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res. 2013; 12(2):821-31. DOI: 10.1021/pr300887z. View

Peracaula R, Barrabes S, Sarrats A, Rudd P, de Llorens R . Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers. 2009; 25(4-5):207-18. PMC: 3827805. DOI: 10.1155/2008/797629. View

10.

Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O . Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J. 2011; 29(1):57-66. DOI: 10.1007/s10719-011-9364-z. View

11.

An H, Kronewitter S, De Leoz M, Lebrilla C . Glycomics and disease markers. Curr Opin Chem Biol. 2009; 13(5-6):601-7. PMC: 2788081. DOI: 10.1016/j.cbpa.2009.08.015. View

12.

Westermann F, Schwab M . Genetic parameters of neuroblastomas. Cancer Lett. 2002; 184(2):127-47. DOI: 10.1016/s0304-3835(02)00199-4. View

13.

Luksch R, Castellani M, Collini P, De Bernardi B, Conte M, Gambini C . Neuroblastoma (Peripheral neuroblastic tumours). Crit Rev Oncol Hematol. 2016; 107:163-181. DOI: 10.1016/j.critrevonc.2016.10.001. View

14.

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

15.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

16.

Lundstrom S, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka S, Soininen H . Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. J Alzheimers Dis. 2013; 38(3):567-79. DOI: 10.3233/JAD-131088. View

17.

de Haan N, Reiding K, Driessen G, van der Burg M, Wuhrer M . Changes in Healthy Human IgG Fc-Glycosylation after Birth and during Early Childhood. J Proteome Res. 2016; 15(6):1853-61. DOI: 10.1021/acs.jproteome.6b00038. View

18.

Kristic J, Vuckovic F, Menni C, Klaric L, Keser T, Beceheli I . Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci. 2013; 69(7):779-89. PMC: 4049143. DOI: 10.1093/gerona/glt190. View

19.

Takahashi N, Ishii I, Ishihara H, Mori M, TEJIMA S, Jefferis R . Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. Biochemistry. 1987; 26(4):1137-44. DOI: 10.1021/bi00378a023. View

20.

Kanoh Y, Mashiko T, Danbara M, Takayama Y, Ohtani S, Egawa S . Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res. 2004; 24(5B):3135-9. View